Pharmaceuticals, Biotechnology & Life Sciences

Imugene Limited expands share structure with ASX listing of extra shares, boosting liquidity, investor base, and support for its cancer vaccine innovations.

Chongqing Taiji Industry’s share volatility sparks regulatory scrutiny—see how the pharma leader’s transparency may stabilize investor confidence.

Explore MannKind Corp’s biopharma journey: diabetes & cancer therapies, volatile Nasdaq stock, $1.26B cap, and future growth prospects.

Novavax’s VLP vaccine tech offers breakthrough promise, but its volatile stock and negative P/E reveal investor caution and the high risk of biotech innovation.

Explore how Eli Lilly’s GLP‑1 drugs are driving multi‑billion growth, defensive resilience, and analyst confidence in today’s volatile pharma market.

Vertex Pharmaceuticals’ $485/share surge follows FDA approval of a new CF drug and the acquisition of CRNX, boosting its biotech pipeline and investor confidence.

Satellos Bioscience shows promising Phase 2 results for its oral DMD drug SAT‑3247, reducing muscle fat and boosting strength while staying safe.

Explore Eli Lilly’s July 2026 market update: analyst upgrades, new Alzheimer’s biomarker data, Canadian eczema approval, and European pricing risks.

Explore how Novo Nordisk’s 19% share surge reflects Wegovy’s success and a bold shift toward diversified biopharma growth.

Phathom Pharmaceuticals tackles GI disease with cutting‑edge therapies, trading at $12.16 on Nasdaq – see its growth potential despite a negative P/E ratio.